Evidence map›Paper›PMID 38241002›Full record

SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024

Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.

Ahmed Atia, Heba Aboeldahab, Ahmed Wageeh, Mohamed Elneny, Mohamed Elmallahy, Bashaer Elawfi, Menna M Aboelkhier, Amr Elrosasy, Maya Magdy Abdelwahab, Somaya Sayed and 1 more

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 5 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 5 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Guideline
  2. Management of brain-heart multimorbidity: a clinical practice guideline.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 2 countries.

Ahmed AtiaMedical Research Group of Egypt (MRGE), Cairo, Egypt.
Heba AboeldahabMedical Research Group of Egypt (MRGE), Cairo, Egypt.
Ahmed WageehFaculty of Medicine, Menoufia University, Menoufia, Egypt.
Mohamed ElnenyDamietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Mohamed ElmallahyFaculty of Medicine, Tanta University, Tanta, Egypt.
Bashaer ElawfiFaculty of Medicine, Sana'a University, Sana'a, Yemen.
Menna M AboelkhierMaster program, Faculty of Science, Suez Canal University, Ismailia, Egypt.
Amr ElrosasyFaculty of Medicine, Cairo University, Cairo, Egypt.
Maya Magdy AbdelwahabFaculty of Medicine, Helwan University, Cairo, Egypt.
Somaya SayedFaculty of Medicine, Minia University, Minya, Egypt.
Ahmed AbdelazizMedical Research Group of Egypt (MRGE), Cairo, Egypt. ahmedmhmd0144@gmail.com.ORCID http://orcid.org/0000-0002-1257-3450
Cairo University · EGAl-Azhar University · EGDamietta University · EGHelwan University · EGMenoufia University · EGMinia University · EGSana'a University · YEScientific Research Group in Egypt · EGSuez Canal University · EGTanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElevated circulating cholesterol levels in patients with acute coronary syndrome (ACS) increase morbidity and mortality. Recent studies reported that PCSK9 inhibitors (PCSK9i) have a beneficial effect on various domains of patients' lipid profiles and cardiovascular and mortality outcomes. Here, we aim to further investigate the efficacy and safety of PCSK9i in patients with ACS or who experienced recent episodes.

methodsWe comprehensively searched PubMed, Scopus, Web of Science and Cochrane CENTRAL to identify all randomized controlled trials comparing PCSK9i versus placebo. Data were extracted and analysed using Stata/MP version 17.0.

resultsEleven studies (n = 24,732) were included in this meta-analysis. In terms of efficacy outcomes, compared with the control group, PCSK9i significantly decreased levels of LDL-C, TC, TG, Lp (a) and Apo-B, with the following values, respectively: Cohen's d of - 1.25, 95% confidence interval (CI - 1.64 to - 0.87); Cohen's d of - 1.32, 95% CI (- 1.83 to - 0.81); Cohen's d of - 0.26, 95% CI (- 0.37 to - 0.14); Cohen's d of - 0.70, 95% CI (- 1.15 to - 0.26); and Cohen's d of - 1.46, 95% CI (- 1.97 to - 0.94). The levels of HDL-C and Apo-A1 increased by: Cohen's d 0.27, 95% CI (0.16-0.39) and Cohen's d of 0.30, 95% CI (0.17-0.42), respectively. Regarding safety outcomes, PCSK9i was associated with lower odds of myocardial infarction (MI) and cerebrovascular events with the following values, respectively: OR = 0.87, 95% CI (0.78-0.97) and OR = 0.71, 95% CI (0.52-0.98).

conclusionsPCSK9i was associated with better lipid profile and quality of life of patients and can be recommended as an optimal treatment strategy. Further trials should study combinations of PCSK9i with other lipid-lowering drugs.

Indexed as

Acute Coronary SyndromeAnticholesteremic AgentsHypercholesterolemiaPCSK9 InhibitorsCholesterol, LDLHumansProprotein Convertase 9Quality of LifeRandomized Controlled Trials as TopicAnticholesteremic AgentsCholesterol, LDLPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Identifiers

PMID38241002
PMCPMC10806009
OpenAlexW4391032824

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.